1. Home
  2. AQB vs GNPX Comparison

AQB vs GNPX Comparison

Compare AQB & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AquaBounty Technologies Inc.

AQB

AquaBounty Technologies Inc.

HOLD

Current Price

$1.00

Market Cap

3.5M

Sector

N/A

ML Signal

HOLD

Logo Genprex Inc.

GNPX

Genprex Inc.

HOLD

Current Price

$1.22

Market Cap

3.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AQB
GNPX
Founded
1991
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5M
3.6M
IPO Year
2017
2017

Fundamental Metrics

Financial Performance
Metric
AQB
GNPX
Price
$1.00
$1.22
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
16.9K
308.8K
Earning Date
05-14-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
87.66
N/A
EPS
N/A
N/A
Revenue
$2,472,659.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.60
$0.14
52 Week High
$2.95
$12.97

Technical Indicators

Market Signals
Indicator
AQB
GNPX
Relative Strength Index (RSI) 59.83 25.60
Support Level $0.86 $0.17
Resistance Level $1.00 $2.12
Average True Range (ATR) 0.04 0.13
MACD 0.01 -0.05
Stochastic Oscillator 82.56 8.54

Price Performance

Historical Comparison
AQB
GNPX

About AQB AquaBounty Technologies Inc.

AquaBounty Technologies Inc is engaged in the field of land-based aquaculture and the use of technology to improve the productivity and sustainability. The company's objective is to ensure the availability of high-quality seafood to meet consumer demand while addressing critical production constraints in the popular farmed species.

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Share on Social Networks: